Advertisement

DNA Topoisomerase II: Promising Target for Anticancer Drugs

  • Paramjeet Kaur
  • Varinder Kaur
  • Satwinderjeet KaurEmail author
Conference paper

Abstract

Topoisomerase II inhibitors are being researched as targets for the generation of antineoplastic drugs because inhibition of topoisomerase II by theses drugs leads to cell death. Inhibitors bind with topoisomerase molecule thus making the enzyme nonfunctional and converting it into a cellular toxin that fragments the genome. Cancer cells divide more rapidly than normal cells. Thus, cancer cells would be killed preferably instead of normal cells by topoisomerase inhibitors. The inhibitors which decrease the overall activity of this enzyme are called catalytic inhibitors and that increase the level of topoisomerase–DNA-cleaved complexes are called poisons. Topoisomerase poisons are further divided into intercalating and non-intercalating. Phytochemicals have proven to be rich sources of topoisomerase II inhibitors and widely used as anticancer drugs, whereas some are components of human diet and known to act as chemopreventive agents. The present review explains the role of both categories of topoisomerase II inhibitors, viz., catalytic inhibitors and poisons, and their role in cancer chemoprevention.

Keywords

Topoisomerase II inhibitors Cancer chemoprevention Anticancer drugs Cancer 

References

  1. Alberts DS, Peng YM, Bowden GT, Dalton WS, Mackel C (1985) Pharmacology of mitoxantrone: mode of action and pharmacokinetics. Invest New Drugs 3(2):101–107PubMedGoogle Scholar
  2. Andoh T, Ishida R (1998) Catalytic inhibitors of DNA topoisomerase II. Biochem Biophys Acta 1400:155–171PubMedGoogle Scholar
  3. Aplan PD, Chervinsky DS, Stanulla M, Burhans WC (1996) Site-specific DNA cleavage within the MLL breakpoint cluster region induced by topoisomerase II inhibitors. Blood 87(7):2649–2658PubMedGoogle Scholar
  4. Austin CA, Barot HA, Margerrison EE, Turcatti G, Wingfield P, Hayes MV, Fisher LM (1990) Structure and partial amino acid sequence of calf thymus DNA topoisomerase II: comparison with other type II enzymes. Biochem Biophys Res Commun 170(2):763–768PubMedCrossRefGoogle Scholar
  5. Azarova AM, Lin RK, Tsai YC, Liu LF, Lin CP, Lyu YL (2010) Genistein induces topoisomerase IIb- and proteasome-mediated DNA sequence rearrangements: implications in infant leukemia. Biochem Biophys Res Commun 399:66–71PubMedCentralPubMedCrossRefGoogle Scholar
  6. Bariar B (2014) Topoisomerase II inhibitors induce an illegitimate genome rearrangement common in infant leukemia. Dissertation, The University of North Carolina at Charlotte. DAI/B74-11(E). Publication number 3589793. ISBN 9781303288661Google Scholar
  7. Bjornsti MA, Benedetti P, Vigilanti GA, Wang JC (1989) Expression of human DNA topoisomerase I in yeast cells lacking yeast DNA topoisomerase I: restoration of sensitivity of the cells to the antitumor drug camptothecin. Cancer Res 49:6318–6321PubMedGoogle Scholar
  8. Boland MP, Fitzgerald KA, ONeill LA (2000) Topoisomerase II is required for mitoxantrone to signal NF-kB activation in HL60 cells. J Biol Chem 275:25231–25238PubMedCrossRefGoogle Scholar
  9. Boritzki TJ, Besserer JA, Jackson RC, Fry DW (1988) Inhibition of type II topoisomerase by fostriecin. Biochem Pharmacol 37:4063–4068PubMedCrossRefGoogle Scholar
  10. Capranico G, Binaschi M (1998) DNA sequence selectivity of topoisomerases and topoisomerase poisons. Biochim Biophys Acta 1400(1–3):185PubMedCrossRefGoogle Scholar
  11. Caron PR, Watt P, Wang JC (1994) The C-terminal domain of Saccharomyces cerevisiae DNA topoisomerase II. Mol Cell Biol 14(5):3197PubMedCentralPubMedGoogle Scholar
  12. Carraway HE, Gore SD (2007) Phase I trial of histone deacetylase inhibition by valproic acid followed by the topoisomerase II inhibitor epirubicin in advanced solid tumors: a clinical and translational study. J Clin Oncol 25(15):1955–1956PubMedCrossRefGoogle Scholar
  13. Champoux JJ (2001) DNA topoisomerase: structure, function and mechanism. Annu Rev Biochem 70:369–413PubMedCrossRefGoogle Scholar
  14. Cooper RG, Magwere T (2008) Chloroquine: novel uses & manifestations. Indian J Med Res 127:305–316PubMedGoogle Scholar
  15. Cowell IG, Austin CA (2012) Mechanism of generation of therapy related leukemias in response to antitopoisomerase II agents. Int J Environ Res Public Health 9:2075–2091PubMedCentralPubMedCrossRefGoogle Scholar
  16. Deweese JE, Burgin AB, Osheroff N (2008) Human topoisomerase IIα uses a two-metal-ion mechanism for DNA cleavage. Nucleic Acids Res 36(15):4883PubMedCentralPubMedCrossRefGoogle Scholar
  17. Downes CS, Clarke DJ, Mullinger AM, Gimenez-Abian JF, Creighton AM, Johnson RT (1994) A topoisomerase II-dependent G2 cycle checkpoint in mammalian cells. Nature 372(6505):467–470PubMedCrossRefGoogle Scholar
  18. Ettinger DS, Finkelstein DM, Ritch PS, Lincoln ST, Blum RH (2002) Study of either ifosfamide or teniposide compared to a standard chemotherapy for extensive disease small cell lung cancer: an Eastern Cooperative oncology Group randomized study. Lung Cancer 37:311–318PubMedCrossRefGoogle Scholar
  19. Felix CA (2001) Leukemias related to treatment with DNA topoisomerase II inhibitors. Med Pediatr Oncol 36:525–535PubMedCrossRefGoogle Scholar
  20. Fisher LM, Rogers MP, Austin CA, Meczes EL, Marsh KL (1997) Complementation of temperature-sensitive topoisomerase II mutations in Saccharomyces cerevisiae by a human TOPOISOMERASE II construct allows the study of topoisomerase II inhibitors in yeast. Cancer Chemother Pharmacol 39:367–375PubMedCrossRefGoogle Scholar
  21. Fogli S, Nieri P, Breschi MC (2004) The role of nitric oxide in anthracycline toxicity and prospects for pharmacologic prevention of cardiac damage. J FASEB 18(6):664–675CrossRefGoogle Scholar
  22. Fortune JM, Osheroff N (2000) Topoisomerase II as a target for anticancer drugs: when enzymes stop being nice. Prog Nucleic Acid Res Mol Biol 64:221–253PubMedCrossRefGoogle Scholar
  23. Foury F (1997) Human genetic diseases: a cross-talk between man and yeast. Gene 195:1–10PubMedCrossRefGoogle Scholar
  24. Gewirtz DA (1999) A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochem Pharmacol 57(7):727–741PubMedCrossRefGoogle Scholar
  25. Giguere A, Hébert J (2011) Microhomologies and topoisomerase II consensus sequences identified near the breakpoint junctions of the recurrent t(7;21)(p22;q22) translocation in acute myeloid leukemia. Genes Chromosomes Cancer 50(4):228–238PubMedGoogle Scholar
  26. Habberstad AH, Gulati S, Torp SH (2011) Evaluation of the proliferation markers Ki-67/MIB-1, mitosin, survivin, pHH3, and DNA topoisomerase IIa in human anaplastic astrocytomas- an immunohistochemical study. Diagn Pathol 6:43PubMedCentralPubMedCrossRefGoogle Scholar
  27. Hajji N, Mateos S, Pastor N, Dominguez I, Cortes F (2005) Induction of genotoxic and cytotoxic damage by aclarubicin, a dual topoisomerase inhibitor. Mutation Res 583:26–35PubMedCrossRefGoogle Scholar
  28. Harker WG, Slade DL, Parr RL, Feldhoff PW, Sullivan DM, Holguin MH (1995) Alterations in the topoisomerase II alpha gene, messenger RNA, and subcellular protein distribution as well as reduced expression of the DNA topoisomerase II beta enzyme in a mitoxantrone-resistant HL-60 human leukemia cell line. Cancer Res 55(8):1707–1716PubMedGoogle Scholar
  29. Hasinoff BB, Abram M, Barnabe N, Khelifa T, Allan W, Yalowich J (2001) The catalytic DNA topoisomerase II inhibitor dexrazoxane (ICRF-187) induces differentiation and apoptosis in human leukemia K562 cells. Mol Pharmacol 59(3):453–461Google Scholar
  30. Hastie CJ, Cohen PT (1998) Purification of protein phosphatase 4 catalytic subunit: inhibition by the antitumour drug fostriecin and other tumour suppressors and promoters. FEBS Lett 431:357–361PubMedCrossRefGoogle Scholar
  31. Heck MM, Earnshaw WC (1986) Topoisomerase II: a specific marker for cell proliferation. J Cell Biol 103(6 Pt 2):2569–2581Google Scholar
  32. Hsiang YH, Wu HY, Liu LF (1988) Proliferation-dependent regulation of DNA topoisomerase II in cultured human cells. Cancer Res 48:3230–3235PubMedGoogle Scholar
  33. Isaacs RJ, Davies SL, Sandri MI, Redwood C, Wells NJ, Hickson ID (1998) Physiological regulation of eukaryotic topoisomerase II. Biochim Biophys Acta 1400:121–137PubMedCrossRefGoogle Scholar
  34. Jackson RC, Fry DW, Boritzki TJ, Roberts BJ, Hooke KE, Leopold WR (1985) Biochemical pharmacology of CI-920, a structurally novel antibiotic with antileukemic activity. Adv Enzyme Regul 23:193–215PubMedCrossRefGoogle Scholar
  35. Jensen S, Andersen AH, Kjeldsen E, Biersack H, Olsen EH, Andersen TB, Westergaard O, Jakobsen BK (1996) Analysis of functional domain organization in DNA topoisomerase II from humans and Saccharomyces cerevisiae. Mol Cell Biol 16(7):3866PubMedCentralPubMedGoogle Scholar
  36. Jobe M, Iwegbu CA, Banful A, Bosier E, Iqbal M, Jones K, Lecutier SJ, Lepper K, Redmond M, Parker AR, Ward E, Wernham P, Whidden EM, Tyler KM, Steverding D (2012) Differential in vitro activity of the DNA topoisomerase inhibitor idarubicin against Trypanosoma rangeli and Trypanosoma cruzi. Mem Inst Oswaldo Cruz 107(7):946–950PubMedCrossRefGoogle Scholar
  37. Karpinich NO, Tafani M, Rothman RJ, Russo MA, Farber JL (2002) The course of etoposide-induced apoptosis from damage to DNA and p53 activation to mitochondrial release of cytochrome c. J Biol Chem 277:16547–16552PubMedCrossRefGoogle Scholar
  38. Kato S, Kikuchi A (1998) DNA topoisomerase: the key enzyme that regulates DNA super structure. J Med Sci 61:11–26Google Scholar
  39. Ketron AC, Osheroff N (2014) Phytochemicals as anticancer and chemoprotective topoisomerase II poisons. Phytochem Rev 13:19–35PubMedCrossRefGoogle Scholar
  40. Kobayashi K, Ratain MJ (1994) Pharmacodynamics and long-term toxicity of etoposide. Cancer Chemother Pharmacol 34:64–68CrossRefGoogle Scholar
  41. Koceva-Chyla A, Jedrzejczak M, Skierski J, Kania K, Jozwiak Z (2005) Mechanisms of induction of apoptosis by anthraquinone anticancer drugs aclarubicin and mitoxantrone in comparison with doxorubicin: relation to drug cytotoxicity and caspase-3 activation. Apoptosis 10(6):1497–1514PubMedCrossRefGoogle Scholar
  42. Kranz JE, Holm C (1990) Cloning by function: an alternative approach for identifying yeast homologs of genes from other organisms. Proc Natl Acad Sci 87:6629–6633PubMedCentralPubMedCrossRefGoogle Scholar
  43. Krohn (2008) Anthracycline chemistry and biology: biological occurrence and biosynthesis, synthesis and chemistry: No. 1. 1 (9 July 2008). In: Krohn K (ed) Topics in current chemistry. Springer, HeidelbergGoogle Scholar
  44. Larsen AK, Escargueil AE, Skladanowski A (2003) Catalytic topoisomerase II inhibitors in cancer therapy. Pharmacol Ther 99(2):167–181PubMedCrossRefGoogle Scholar
  45. Lehmann M, Vilar Kde S, Franco A, Reguly ML, Rodrigues de Andrade HH (2004) Activity of topoisomerase inhibitors daunorubicin, idarubicin, and aclarubicin in the drosophila somatic mutation and recombination test. Environ Mol Mutagen 43(4):250–257PubMedCrossRefGoogle Scholar
  46. Leopold WR, Shillis JL, Mertus AE, Nelson JM, Roberts BJ, Jackson RC (1984) Anticancer activity of structurally novel antibiotic CI-920 and its analogues. Cancer Res 44:1928–1932PubMedGoogle Scholar
  47. Lorenzo GD, Rea A, Carlomagno C, Pepe S, Palmieri G, Labianca R, Chirianni A, Stefano AD, Esposito V, Placido SD, Montesarchio V (2007) Activity and safety of pegylated liposomal doxorubicin, 5-fluorouracil and folinic acid in inoperable hepatocellular carcinoma: a phase II study. World J Gastroenterol 13(48):6553–6557PubMedCrossRefGoogle Scholar
  48. Lynch BJ, Guinee DG Jr, Holden JA (1997) Human DNA topoisomerase II-alpha: a new marker of cell proliferation in invasive breast cancer. Hum Pathol 28(10):1180–1188PubMedCrossRefGoogle Scholar
  49. Mc Clendona AK, Osheroff N (2007) DNA topoisomerase II, genotoxicity, and cancer. Mutat Res 623:83–97CrossRefGoogle Scholar
  50. Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L (2004) Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev 56:185–229PubMedCrossRefGoogle Scholar
  51. Nitiss JL (2009a) Targeting DNA topoisomerase II in cancer chemotherapy. Nat Rev Cancer 9:338–350PubMedCentralPubMedCrossRefGoogle Scholar
  52. Nitiss JL (2009b) DNA topoisomerase II and its growing repertoire of biological functions. Nat Rev Cancer 9(5):327PubMedCentralPubMedCrossRefGoogle Scholar
  53. Otake Y, Mims A, Fernandes D (2006) Merbarone induces activation of caspase-activated DNase and excision of chromosomal DNA loops from the nuclear matrix. Mol Pharmacol 69(4):1477–1485PubMedCrossRefGoogle Scholar
  54. Park Y, Kim EJ, Park HJ, Fields K, Dunker AK, Kang CH (2005) Interaction between cardiac calsequestrin and drugs with known cardiotoxicity. Mol Pharmacol 67:97–104PubMedCrossRefGoogle Scholar
  55. Pastor N, Domínguez I, Orta ML, Campanella C, Mateos S, Cortes F (2012) The DNA topoisomerase II catalytic inhibitor merbarone is genotoxic and induces endoreduplication. Mutat Res 738–739:45–51PubMedCrossRefGoogle Scholar
  56. Permana PA, Snapka RM, Shen LL, Chu DTW, Clement JJ, Plattner JJ (1994) Quinobenoxazines: a class of novel antitumor quinolines and potent mammalian DNA topoisomerase II catalytic inhibitors. Biochemistry 33:11333–11339Google Scholar
  57. Petita T, Wiltb M, Veltenc M, Millond R, Rodiere JF, Borela C, Morsa R, Haegele P, Eberd M, Ghnassiab JP (2004) Comparative value of tumour grade, hormonal receptors, Ki-67, HER-2 and topoisomerase II alpha status as predictive markers in breast cancer patients treated with neoadjuvant anthracycline-based chemotherapy. Eur J Cancer 40:205–211CrossRefGoogle Scholar
  58. Pommier Y (2013) Drugging topoisomerases: lessons and challenges. ACS Chem Biol 8:82–95PubMedCentralPubMedCrossRefGoogle Scholar
  59. Relling MV, Pui CH, Sandiund JT, Rivera GK, Hancock ML, Boyett JM (2000) Adverse effect of anticonvulsants on efficacy of chemotherapy for acute lymphoblastic leukaemia. Lancet 356:285–290PubMedCrossRefGoogle Scholar
  60. Roca J, Wang JC (1994) DNA transport by a type II DNA topoisomerase: evidence in favor of a two-gate mechanism. Cell 77(4):609PubMedCrossRefGoogle Scholar
  61. Ross JA (2000) Dietary flavonoids and the MLL gene: a pathway to infant leukemia. Proc Natl Acad Sci U S A 97:4411–4413PubMedCentralPubMedCrossRefGoogle Scholar
  62. Schoeffler AJ, Berger JM (2005) Recent advances in understanding structure-function relationships in the type II topoisomerase mechanism. Biochem Soc Trans 33(6):1465PubMedCrossRefGoogle Scholar
  63. Scott LJ, Figgitt DP (2004) Mitoxantrone: a review of its use in multiple sclerosis. CNS Drugs 18(6):379–396PubMedCrossRefGoogle Scholar
  64. Shiozaki K, Yanagida M (1991) A functional 125-kDa core polypeptide of fission yeast DNA topoisomerase II. Mol Cell Biol 11(12):6093PubMedCentralPubMedGoogle Scholar
  65. Stahelin HF, von Wartburg A (1991) The chemical and biological route from podophyllotoxin glucoside to etoposide: ninth Cain memorial Award lecture. Cancer Res 51:5–15PubMedGoogle Scholar
  66. Surh Y-J (2003) Cancer chemoprevention with dietary phytochemicals. Nat Rev Cancer 3:768–780PubMedCrossRefGoogle Scholar
  67. Thakur DS (2011) Topoisomerase II inhibitors in cancer treatment. Int J Pharmac Sci Nanotechnol 3(4):1173–1181Google Scholar
  68. Thigpen JT (2004) Innovations in anthracycline therapy: overview. Commun Oncol 2(1):3–7Google Scholar
  69. Thuy TT, Lee HC, Kim CG, Heide L, Sohng JK (2005) Functional characterizations of novWUS involved in novobiocin biosynthesis from Streptomyces spheroides. Arch Biochem Biophys 436(1):161–167PubMedCrossRefGoogle Scholar
  70. Treszezamsky AD, Kachnic LA, Feng Z et al (2007) BRCA1 and BRCA2 deficient cells are sensitive to etoposide-induced DNA double-strand breaks via topoisomerase II. Cancer Res 67:7078–7081PubMedCrossRefGoogle Scholar
  71. Tse YC, Kirkegaard K, Wang JC (1980) Covalent bonds between protein and DNA. Formation of phosphotyrosine linkage between certain DNA topoisomerases and DNA. J Biol Chem 255(12):5560–5565PubMedGoogle Scholar
  72. Ueki Y, Naito I, Oohashi T, Sugimoto M, Seki T, Yoshioka H, Sado Y, Sato H, Sawai T, Sasaki F, Matsuoka M, Fukuda S, Ninomiya Y (1998) Topoisomerase I and II consensus sequences in a 17-kb deletion junction of the COL4A5 and COL4A6 genes and immunohistochemical analysis of esophageal leiomyomatosis associated with Alport syndrome. Am J Hum Genet 62(2):253–261PubMedCentralPubMedCrossRefGoogle Scholar
  73. Van Maanen JM, Retèl J, de Vries J, Pinedo HM (1988) Mechanism of action of antitumor drug etoposide: a review. J Natl Cancer Inst 80(19):1526–1533PubMedCrossRefGoogle Scholar
  74. Vejpongsa P, Yeh ETH (2014) Topoisomerase 2β: a promising molecular target for primary prevention of anthracycline-induced cardiotoxicity. Clin Pharmacol Ther 95:45–52PubMedCrossRefGoogle Scholar
  75. Walsh AH, Cheng A, Honkanen RE (1997) Fostriecin, an antitumor antibiotic with inhibitory activity against serine/threonine protein phosphatases types 1 (PP1) and 2A (PP2A), is highly selective for PP2A. FEBS Lett 416(3):230–234PubMedCrossRefGoogle Scholar
  76. Wang JC (2002) Cellular roles of DNA topoisomerases: a molecular perspective. Reviews. Nature Publishing Group 3:430Google Scholar
  77. Wang L, Roy SK, Eastmond DA (2007) Differential cell cycle specificity for chromosomal damage induced by merbarone and etoposide in V79 cells. Mutat Res 616(1–2):70–82Google Scholar
  78. Wilson CS, Medeiros LJ, Lai R, Butch AW, McCourty A, Kelly K, Brynes RK (2001) DNA topoisomerase II in multiple myeloma: a marker of cell proliferation and not drug resistance. Mod Pathol 14(9):886–891PubMedCrossRefGoogle Scholar
  79. Wilstermann AM, Osheroff N (2003) Stabilization of eukaryotic topoisomerase II-DNA cleavage complexes. Curr Top Med Chem 3(18):321–338PubMedCrossRefGoogle Scholar
  80. Wiseman LR, Spencer CM (1997) Mitoxantrone. A review of its pharmacology and clinical efficacy in the management of hormone-resistant advanced prostate cancer. Drugs Aging 10(6):473–485PubMedCrossRefGoogle Scholar
  81. Woessner RD, Mattern MR, Mirabelli CK, Johnson RK, Drake FH (1991) Proliferation- and cell cycle-dependent differences in expression of the 170 kilodalton and 180 kilodalton forms of topoisomerase II in NIH-3 T3 cells. Cell Growth Differ 2:209–214PubMedGoogle Scholar
  82. Zhang S, Liu X, Bawa-Khalfe T, Lu LS, Lyu YL, Liu LF, Yeh ET (2012) Identification of the molecular basis of doxorubicin-induced cardiotoxicity. Nat Med 18(11):1639–1642PubMedCrossRefGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2015

Authors and Affiliations

  • Paramjeet Kaur
    • 1
  • Varinder Kaur
    • 1
  • Satwinderjeet Kaur
    • 1
    Email author
  1. 1.Department of Botanical and Environmental SciencesGuru Nanak Dev UniversityAmritsarIndia

Personalised recommendations